What is the consensus rating for BIONOMICS LTD-ADR (BNOX) stock?
The consensus rating for BIONOMICS LTD-ADR (BNOX) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
BIONOMICS LTD-ADR (BNOX) Forecast, Price Target & Analyst Ratings
NASDAQ:BNOX • US09063M2052
Current stock price
0.2531 USD
+0.01 (+4.2%)
At close:
0.4002 USD
+0.15 (+58.12%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIONOMICS LTD-ADR (BNOX).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.25 to mean target of N/A, Based on 8 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
BNOX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about BNOX.
In the previous month the buy percentage consensus was at a similar level.
BNOX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-28 | Maxim Group | Maintains | Buy -> Buy |
| 2023-09-28 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2023-06-16 | Maxim Group | Initiate | Buy |
| 2023-03-10 | Evercore ISI Group | Upgrade | In-Line -> Outperform |
| 2023-03-09 | Loop Capital | Maintains | Buy |
| 2023-03-09 | HC Wainwright & Co. | Maintains | Neutral |
| 2022-12-20 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-12-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-11-01 | Loop Capital | Initiate | Buy |
| 2022-01-10 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-01-10 | Berenberg | Initiate | Buy |
| 2022-01-10 | Evercore ISI Group | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | -100.00% | 164.769K | 22.05K -86.62% | 633.655K 2,773.72% | 977.619K 54.28% | 34.297M 3,408.22% | |
| EBITDA YoY % growth | N/A -253.57% | N/A -205.12% | -32.3M -141.36% | -23.328M 27.78% | -27.913M -19.65% | N/A | |
| EBIT YoY % growth | -5.424M -111.72% | -13.92M -156.63% | -32.963M -136.81% | -21.855M 33.70% | -26.135M -19.58% | -37.947M -45.20% | |
| Operating Margin | N/A | -8,447.89% | -149,490.84% | -3,449.09% | -2,673.29% | -110.64% | |
| EPS YoY % growth | -0.01 99.51% | -0.02 -130.00% | N/A -8,576.43% | -1.32 33.83% | -0.70 46.79% | -3.18 -352.05% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-16.76%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
118.41%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A